Skip to search formSkip to main contentSkip to account menu

reparixin

Known as: (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide, Benzeneacetamide, Alpha-methyl-4-(2-methylpropyl)-N- (methylsulfonyl)- (alphaR)-, Repertaxin 
An orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Cancer stem cells (CSCs) are purported to be responsible for tumor initiation, treatment resistance, disease recurrence, and… 
Highly Cited
2017
Highly Cited
2017
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer
Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor selectively expressed by breast cancer stem cells… 
Highly Cited
2011
Highly Cited
2011
A Self-Propagating Matrix Metalloprotease-9 (MMP-9) Dependent Cycle of Chronic Neutrophilic Inflammation
Background Chronic neutrophilic inflammation is a poorly understood feature in a variety of diseases with notable worldwide… 
Highly Cited
2009
Highly Cited
2009
Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNγ production
IL-23/IL-17-induced neutrophil recruitment plays a pivotal role in rheumatoid arthritis (RA). However, the mechanism of the… 
Highly Cited
2008
Highly Cited
2008
Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice
Acute lung injury (ALI) remains a major challenge in critical care medicine. Both neutrophils and chemokines have been proposed… 
Review
2006
Review
2006
ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
Highly Cited
2005
Highly Cited
2005
Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion.
BACKGROUND Ischemia/reperfusion (I/R) injury after organ transplantation is a major cause of delayed graft function. Following I… 
Highly Cited
2005
Highly Cited
2005
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at… 
Highly Cited
2004
Highly Cited
2004
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.
The chemokine CXC ligand 8 (CXCL8)/IL-8 and related agonists recruit and activate polymorphonuclear cells by binding the CXC… 
Highly Cited
2004
Highly Cited
2004
Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury
Neutrophils are thought to play a major role in the mediation of reperfusion injury. CXC chemokines are known inducers of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)